Viking Therapeutics

Viking Therapeutics' VK2735 is a dual GLP-1/GIP receptor agonist that produced ~13.1% mean weight loss at 13 weeks in Phase 2 — a notable speed of effect, faster than tirzepatide reaches comparable loss in its standard titration schedule. Viking is developing both subcutaneous and oral formulations of VK2735.

The clinical-stage thesis is that VK2735's faster onset (driven by a different receptor-binding profile) could carve out a tolerability or speed-of-result advantage even in a market increasingly dominated by Lilly and Novo's higher-volume manufacturing. The downside is exposure: a small biotech building one molecule into a therapeutic area where the incumbents have decade-long manufacturing leadership.

VKTX has been one of the more volatile mid-cap biotech tickers as Phase 2 data and Phase 3 commitments have moved the stock by 20-40% in single sessions. Editorial caution — this company's valuation is data-dependent in a way the larger names aren't.